Galectin-9-based immune risk score model helps to predict relapse in stage I–III small cell lung cancer

BACKGROUND: For small cell lung cancer (SCLC) therapy, immunotherapy might have unique advantages to some extent. Galectin-9 (Gal-9) plays an important role in antitumor immunity, while little is known of its function in SCLC. MATERIALS AND METHODS: By mean of immunohistochemistry (IHC), we tested t...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Immunother Cancer
Auteurs principaux: Chen, Peixin, Zhang, Liping, Zhang, Wei, Sun, Chenglong, Wu, Chunyan, He, Yayi, Zhou, Caicun
Format: Artigo
Langue:Inglês
Publié: BMJ Publishing Group 2020
Sujets:
Immunotherapy Biomarkers
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7577067/
https://ncbi.nlm.nih.gov/pubmed/33082168
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001391
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires